^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PIK3CA E542K

    i
    Other names: PIK3CA, Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, Phosphoinositide-3-kinase, catalytic, alpha polypeptide, Serine/threonine protein kinase PIK3CA, PtdIns-3-kinase subunit P110-alpha, PI3K-alpha, Phosphatidylinositol-4,5-bisphosphate 3-kinase 110 KDa catalytic subunit alpha, Phosphatidylinositol 3-kinase, Catalytic, 110-KD, alpha, PI3-kinase P110 subunit alpha, PI3-kinase subunit alpha, PtdIns-3-kinase subunit alpha, PI3Kalpha, P110alpha, PI3K
    Entrez ID:
    5290
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    Related tests:
    Apply
    Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors (NCT02688881)
    Phase 4
    Samsung Medical Center
    Completed
    Last update posted :
    06/15/2022
    Initiation :
    02/05/2017
    Primary completion :
    12/30/2020
    Completion :
    02/24/2021
    PIK3CA • PTEN
    |
    PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA amplification • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • AKT1 amplification
    |
    sirolimus
    BKM120 in Cancers With PIK3CA Activating Mutations (NCT01501604)
    Phase 2
    Massachusetts General Hospital
    Withdrawn
    Last update posted :
    09/17/2015
    Initiation :
    01/01/2012
    Primary completion :
    08/01/2013
    Completion :
    08/01/2013
    PIK3CA
    |
    PIK3CA mutation • PIK3CA H1047R • PIK3CA E545K • PIK3CA E542K • PIK3CA E545 • PIK3CA E542 • PIK3CA H1047L
    |
    buparlisib (AN2025)